Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

665 ARTÍCULOS , VIENDO DEL 436 AL 450

Differential response to donepezil in MRI subtypes of mild cognitive impairment

Diaz-Galvan P, Lorenzon G, Mohanty R, Mårtensson G, Cavedo E, Lista S, Vergallo A, Kantarci K, Hampel H, Dubois B, Grothe MJ, Ferreira D, Westman E.

Alzheimers Res Ther. 2023 Jun 23;15(1):117. doi: 10.1186/s13195-023-01253-2.

Caffeine for Prevention of Alzheimer's Disease: Is the A(2A) Adenosine Receptor Its Target?

Merighi S, Travagli A, Nigro M, Pasquini S, Cappello M, Contri C, Varani K, Vincenzi F, Borea PA, Gessi S.

Biomolecules. 2023 Jun 8;13(6):967. doi: 10.3390/biom13060967.

Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis

Wu S, Stogios N, Hahn M, Navagnanavel J, Emami Z, Chintoh A, Gerretsen P, Graff-Guerrero A, Rajji TK, Remington G, Agarwal SM.

PLoS One. 2023 Jun 28;18(6):e0286887. doi: 10.1371/journal.pone.0286887. eCollection 2023.

The complex pathway between amyloid β and cognition: implications for therapy

Jagust WJ, Teunissen CE, DeCarli C.

Lancet Neurol. 2023 Sep;22(9):847-857. doi: 10.1016/S1474-4422(23)00128-X. Epub 2023 Jul 13.

Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?

Manly JJ, Deters KD.

JAMA. 2023 Aug 8;330(6):510-511. doi: 10.1001/jama.2023.11704.

Effect of acupuncture on episodic memory for amnesia-type mild cognitive impairment: study protocol of a multicenter, randomized, controlled trial

Dai Y, Xia R, Wang D, Li S, Yuan X, Li X, Liu J, Wang M, Kuang Y, Chen S.

BMC Complement Med Ther. 2023 Jul 28;23(1):268. doi: 10.1186/s12906-023-04059-9.

Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus

Pelle MC, Zaffina I, Giofrè F, Pujia R, Arturi F.

Int J Mol Sci. 2023 Jul 11;24(14):11301. doi: 10.3390/ijms241411301.

The GABA system, a new target for medications against cognitive impairment-Associated with neuroactive steroids

Bäckström T, Turkmen S, Das R, Doverskog M, Blackburn TP.

J Intern Med. 2023 Sep;294(3):281-294. doi: 10.1111/joim.13705. Epub 2023 Jul 30.

Targeting impaired nutrient sensing via the sirtuin pathway with novel compounds to prevent or treat dementia: A systematic review

Matysek A, Sun L, Kimmantudawage SP, Feng L, Maier AB.

Ageing Res Rev. 2023 Sep;90:102029. doi: 10.1016/j.arr.2023.102029. Epub 2023 Aug 6.

Neurovascular glial unit: A target of phytotherapy for cognitive impairments

Chen L, Zhen Y, Wang X, Wang J, Zhu G.

Phytomedicine. 2023 Oct;119:155009. doi: 10.1016/j.phymed.2023.155009. Epub 2023 Aug 2.

A Systematic Compilation of Human SH3 Domains: A Versatile Superfamily in Cellular Signaling

Mehrabipour M, Jasemi NSK, Dvorsky R, Ahmadian MR.

Cells. 2023 Aug 12;12(16):2054. doi: 10.3390/cells12162054.

Antiseizure Medications in Alzheimer's Disease from Preclinical to Clinical Evidence

Bosco F, Guarnieri L, Rania V, Palma E, Citraro R, Corasaniti MT, Leo A, De Sarro G.

Int J Mol Sci. 2023 Aug 10;24(16):12639. doi: 10.3390/ijms241612639.

[Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer's Patients: A Prospective Comparative Study]

Selezneva ND, Gavrilova SI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(8):90-97. doi: 10.17116/jnevro202312308190.

Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease

Kurkinen M.

Adv Clin Exp Med. 2023 Sep;32(9):943-947. doi: 10.17219/acem/171379.

Handwriting Changes in Alzheimer's Disease: A Systematic Review

Fernandes CP, Montalvo G, Caligiuri M, Pertsinakis M, Guimarães J.

J Alzheimers Dis. 2023;96(1):1-11. doi: 10.3233/JAD-230438.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias